文献速递呼吸危重症与机械通气

早期血管内事件与急性呼吸窘迫综合征发生相关:LIPS-A试验亚组分析

Early Intravascular Events Are Associated with Development of Acute Respiratory Distress Syndrome. A Substudy of the LIPS-A Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该研究为多中心双盲临床试验LIPS-A的亚组分析,纳入367例有ARDS风险的患者,随机接受阿司匹林或安慰剂。基线ATL水平、总单核细胞计数、中间型单核细胞计数及单核细胞-血小板聚集体与ARDS发生相关;阿司匹林显著降低TXB2并提高ATL/TXB2比值。结论认为血管内单核细胞活化生物标志物与ARDS发生相关,早期阿司匹林预防ARDS的潜在临床获益仍不确定。

要点

  • 基线ATL、总单核细胞、中间型单核细胞及单核细胞-血小板聚集体与ARDS发生相关。
  • 阿司匹林较安慰剂显著降低TXB2并提高ATL/TXB2比值。
  • 早期阿司匹林预防ARDS的临床获益仍不确定。

核心结论

  • 有ARDS风险患者中血管内单核细胞活化生物标志物与ARDS发生相关。
  • 早期阿司匹林预防ARDS的潜在临床获益仍不确定。

研究设计与样本

  • 多中心、双盲临床试验LIPS-A(NCT01504867)的亚组分析,比较阿司匹林与安慰剂。

主要发现

  • 基线ATL水平、总单核细胞计数、中间型单核细胞计数及单核细胞-血小板聚集体与ARDS发生相关。
  • 外周血中性粒细胞计数和单核细胞-血小板聚集体随时间显著下降。
  • 9例在随机化后、研究药物启动前发生ARDS,其中7例分配至阿司匹林组。
  • 首次给药时无ARDS的受试者中,阿司匹林治疗组ARDS发生率较低。
  • 与安慰剂相比,阿司匹林显著降低TXB2并提高ATL/TXB2比值。

关键数值与推荐

  • 9例在随机化后、研究药物启动前发生ARDS,其中7例分配至阿司匹林组。

临床怎么用

  • 基线单核细胞活化相关生物标志物可能有助于识别ARDS高风险患者。
  • 早期阿司匹林用于ARDS预防的临床获益尚不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. OBJECTIVES: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. METHODS: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. MEASUREMENTS AND MAIN RESULTS: Thirty-three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. CONCLUSIONS: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk. Clinical trial registered with www.clinicaltrials.gov (NCT01504867).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Abdulnour RE, Gunderson T, Barkas I, et al. Early Intravascular Events Are Associated with Development of Acute Respiratory Distress Syndrome. A Substudy of the LIPS-A Clinical Trial. Am J Respir Crit Care Med. 2018. PMID: 29782179. doi:10.1164/rccm.201712-2530OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。